Silicon Valley Startup Pursues AI-Driven Embryo Gene Editing Despite Global Ban

Thumbnail Image

The information displayed in the AIM should not be reported as representing the official views of the OECD or of its member countries.

Silicon Valley startup Preventive, backed by Sam Altman and Brian Armstrong, is developing AI-enabled embryo gene editing to prevent hereditary diseases. Despite global bans and ethical concerns, the company seeks to create genetically modified babies, raising significant risks of future harm but with no confirmed incidents yet.[AI generated]

Why's our monitor labelling this an incident or hazard?

The article describes a start-up working on gene editing technologies to modify embryos, which likely involves AI systems for complex genetic analysis and editing. While no direct harm has occurred yet, the potential for significant ethical, human rights, and societal harms is credible and plausible, especially given the controversial nature of embryo genetic modification and the exploration of conducting research in countries with more permissive laws. The event does not describe realized harm but highlights a credible risk of future harm, fitting the definition of an AI Hazard rather than an AI Incident or Complementary Information.[AI generated]
AI principles
AccountabilityRespect of human rightsSafetyDemocracy & human autonomy

Industries
Healthcare, drugs, and biotechnology

Affected stakeholders
ChildrenGeneral public

Harm types
Physical (injury)Human or fundamental rightsPublic interest

Business function:
Research and development

AI system task:
Reasoning with knowledge structures/planning


Articles about this incident or hazard